Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Gilead to Take Over MA for HIV Franchise from JT on Dec. 1
The Japan arm of Gilead Sciences said on September 2 that it will take over the marketing authorization (MA) of six HIV products from its long-term licensing partner Japan Tobacco on December 1 - officially wrapping up their 16-year collaboration…
To read the full story
Related Article
- Gilead Files HIV Triplet Biktarvy in Japan, JT Pact Termination Set for Jan. 1
December 17, 2018
- JT to Return Rights to Gilead’s 6 HIV Agents in 2019, Get 63.1 Billion Yen
November 30, 2018
- Gilead Japan Looks to End HIV Pacts with JT as It Seeks Long-Term Growth: Chief
August 28, 2018
- Gilead, JT Start Talks on Terminating Japan HIV Pacts
August 27, 2018
BUSINESS
- China First to Approve Takeda’s Oveporexton for Narcolepsy
July 24, 2026
- Torii to Transfer Locoid MA in Japan to Cheplapharm
July 24, 2026
- Japan Vaccine Market Seen Flat in FY2026; Efluelda Delay Clouds Outlook
July 24, 2026
- Nipro Recalls Febuxostat after Finding Expired API Use at Another Plant
July 23, 2026
- Novo’s Koriyama Plant Achieves Net-Zero CO2 Emissions
July 23, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…